Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DNA Sequencing Reveals Mucosal Melanoma's Bullseye

Published: Wednesday, June 12, 2013
Last Updated: Wednesday, June 12, 2013
Bookmark and Share
Scientists have found a molecular 'bullseye' for a rare form of melanoma, opening up opportunities for new targeted treatment.

DNA sequencing carried out at Cancer Research UK’s Paterson Institute for Cancer Research at the University of Manchester has revealed that the genetic fingerprint of mucosal melanoma is completely different from that of its more common counterpart – cutaneous or melanoma skin cancer.

The study has also revealed for the first time the genetic faults against which new treatments could be targeted for mucosal melanoma patients.

Unlike cutaneous melanoma, for which UV is a well-known risk-factor, little is known about the causes of mucosal melanoma. This means there are no treatments that can target the cancer, leading to starkly contrasting outlooks in these two forms of the disease. Five year survival rates for mucosal melanoma are around 40 per cent, compared to more than 90 per cent for cutaneous. There are around 120-130 cases of mucosal melanoma diagnosed each year in the UK.

Professor Richard Marais, director of the Paterson Institute for Cancer Research and lead author of the research, said: “We’ve seen a completely different gene profile in mucosal melanoma. There’s no classic UV signature, which reinforces our thoughts that this type of cancer isn’t linked to the sun and sunbeds and suggests that these types of melanoma start in different ways.

“We can start to look at these newly discovered genetic faults and develop desperately needed targeted treatments for this type of melanoma. It’s exactly this type of vital research that we and other scientists will be doing at the new Manchester Cancer Research Centre – bringing together a wide range of expertise to revolutionise cancer treatment.”

This research was funded by The Catalyst Club, a pioneering venture that's raising £10 million towards personalised cancer treatment. The club is made up of philanthropists who have invested in a range of projects that will help to bring forward the day when all cancers are cured.

Professor Nic Jones, Cancer Research UK’s chief scientist, said: “In effect, these two sub-types of melanoma are more like different diseases that just happen to affect the same cells. Cutaneous melanoma is strongly linked to UV exposure, number of moles, family history and ethnicity, while mucosal melanoma doesn’t seem to be linked to these factors. But it’s usually more aggressive and more likely to spread to other parts of the body than cutaneous melanoma.

“Research like this is helping us to better understand how this disease works and is the first step towards developing more effective treatments. By recognising the differences between sub-types of melanoma, we will be able to tailor treatment for patients so they have the best chance of beating the disease.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Companies Join Cancer Research UK Consortium
Three new biomarker companies have been selected to work with the Early Diagnosis Consortium, a collaboration between Cancer Research UK, its commercial arm, Cancer Research Technology and Abcodia.
Thursday, December 11, 2014
Scientists Find New Drug Target for Hard-to-Treat Leukaemia
Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival.
Friday, March 30, 2012
Cancer Research UK Launches Medicine Manufacturing Hub for Life-Saving Research
New £18 million drug manufacturing facility will make experimental medicine and antibodies to target cancer cells.
Tuesday, August 03, 2010
Scientific News
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
Study Identifies the Off Switch for Biofilm Formation
New discovery could help prevent the formation of infectious bacterial films on hospital equipment.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
X-ray Laser Experiment Could Help in Designing Drugs for Brain Disorders
Scientists found that when two protein structures in the brain join up, they act as an amplifier for a slight increase in calcium concentration, triggering a gunshot-like release of neurotransmitters from one neuron to another.
Team Identifies Structure of Tumor-Suppressing Protein
An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!